These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 12599600

  • 1. [Hormonal therapy for benign prostatic hyperplasia].
    Sakai H, Kanetake H.
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():358-61. PubMed ID: 12599600
    [No Abstract] [Full Text] [Related]

  • 2. Benign prostatic hypertrophy: update on drug therapy.
    Tejani A, Musini V, Perry TL, Mintzes B, Wright JM.
    Can Fam Physician; 2006 Sep; 52(9):1075-6, 1077-8. PubMed ID: 17279217
    [No Abstract] [Full Text] [Related]

  • 3. Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride.
    Shibata Y, Fukabori Y, Ito K, Suzuki K, Yamanaka H.
    J Urol; 2001 Jan; 165(1):289-93. PubMed ID: 11125427
    [Abstract] [Full Text] [Related]

  • 4. [5alpha-dihydrotestosterone (DHT)].
    Komiya A, Suzuki H, Ichikawa T.
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():452-6. PubMed ID: 16149549
    [No Abstract] [Full Text] [Related]

  • 5. Finasteride for benign prostatic hyperplasia.
    Hasinski S, Miller JL, Rose LI.
    Am Fam Physician; 1992 Nov; 46(5):1511-4. PubMed ID: 1279965
    [Abstract] [Full Text] [Related]

  • 6. Prevalent decrease of the EGF content in the periurethral zone of BPH tissue induced by treatment with finasteride or flutamide.
    Monti S, Sciarra F, Adamo MV, Toscano V, Trotta MC, Martini C, Lanzara S, Silverio FD.
    J Androl; 1997 Nov; 18(5):488-94. PubMed ID: 9349746
    [Abstract] [Full Text] [Related]

  • 7. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
    Botto H, Lan O, Poulain JE, Comenducci A.
    Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
    [Abstract] [Full Text] [Related]

  • 8. [Drug treatment of benign prostatic hyperplasia].
    Schmid HP.
    Praxis (Bern 1994); 1995 Sep 26; 84(39):1061-2. PubMed ID: 7481307
    [No Abstract] [Full Text] [Related]

  • 9. 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.
    Dörsam J, Altwein J.
    Prostate Cancer Prostatic Dis; 2009 Sep 26; 12(2):130-6. PubMed ID: 19030020
    [Abstract] [Full Text] [Related]

  • 10. Finasteride upregulates expression of androgen receptor in hyperplastic prostate and LNCaP cells: implications for chemoprevention of prostate cancer.
    Hsieh JT, Chen SC, Yu HJ, Chang HC.
    Prostate; 2011 Jul 26; 71(10):1115-21. PubMed ID: 21557276
    [Abstract] [Full Text] [Related]

  • 11. The concentrations of the endogenous C19-steroids in hyperplastic prostatic tissue and the effect of finasteride treatment.
    Hill M, Petrik R, Hampl R, Stárka L.
    Horm Metab Res; 1996 Oct 26; 28(10):562-4. PubMed ID: 8934217
    [Abstract] [Full Text] [Related]

  • 12. Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer.
    van der Sluis TM, Meuleman EJ, van Moorselaar RJ, Bui HN, Blankenstein MA, Heijboer AC, Vis AN.
    BJU Int; 2012 Jan 26; 109(2):183-8. PubMed ID: 21992404
    [Abstract] [Full Text] [Related]

  • 13. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.
    McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E.
    J Clin Endocrinol Metab; 1992 Mar 26; 74(3):505-8. PubMed ID: 1371291
    [Abstract] [Full Text] [Related]

  • 14. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
    Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S.
    J Clin Endocrinol Metab; 2004 May 26; 89(5):2179-84. PubMed ID: 15126539
    [Abstract] [Full Text] [Related]

  • 15. [Dual 5-alpha reductase inhibitors in BPH (benign prostatic hyperplasia). Already after 1 month prostate shrinks].
    MMW Fortschr Med; 2003 Feb 27; 145(9):54. PubMed ID: 12666533
    [No Abstract] [Full Text] [Related]

  • 16. Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens.
    Marks LS, Hess DL, Dorey FJ, Luz Macairan M, Cruz Santos PB, Tyler VE.
    Urology; 2001 May 27; 57(5):999-1005. PubMed ID: 11337315
    [Abstract] [Full Text] [Related]

  • 17. Chemoprevention of prostate cancer.
    Walsh PC.
    N Engl J Med; 2010 Apr 01; 362(13):1237-8. PubMed ID: 20357287
    [No Abstract] [Full Text] [Related]

  • 18. [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].
    Bartsch G, Rittmaster RS, Klocker H.
    Urologe A; 2002 Sep 01; 41(5):412-24. PubMed ID: 12426858
    [Abstract] [Full Text] [Related]

  • 19. Medical treatment of benign prostatic hyperplasia.
    Schmidt JD.
    West J Med; 1991 Dec 01; 155(6):633. PubMed ID: 1725942
    [No Abstract] [Full Text] [Related]

  • 20. Role of 5α-reductase inhibitors in prostate cancer prevention and treatment.
    Azzouni F, Mohler J.
    Urology; 2012 Jun 01; 79(6):1197-205. PubMed ID: 22446342
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.